abstract: The aim of the study was to investigate whether emotional stress in a pregnant @entity0 might have an adverse effect in the form of @entity2 on fetal development. The @entity0 of 1,263 @entity0 whose applications for legal abortion in 1960 had been refused were compared with the next @entity0 born in the same delivery wards and paired matched controls were thereby obtained. Results. 1) The incidence of @entity2 according to the criteria established by the Swedish Register of Malformations was 1.8% in the proband series as against 1.1% in the control series. 2) The incidence of @entity2 increased with higher age and lower social class in the proband series, whereas no such connection was found in the control series. 3) The incidence of @entity2 for @entity0 of abortion applicants 25 years of age and above from social class III was 3% in the proband series as against 0.6% in the control series (P = 0.017). 4) One @entity2 , @entity5 , occurred at a significantly (P less than 0.01) higher incidence than in the country as a whole, four cases against the expected value of 0.69. 5) Etiological analysis showed that three of the cases were @entity4 , all of them @entity3 , in two cases there was a genetic background and two cases were @entity6 -induced @entity7 . In three proband @entity0 there may have been a connection with the abuse of @entity1 by the mother. 6) When the chromosomal, genetic and thalidomide cases are excluded, the preponderance of @entity2 in the proband @entity0 of mothers 25 years of age and above belonging to social class III still remains (2.2% vs. 0.3%, P = 0.017). Conclusion. The results may be seen as support for the hypothesis that emotional stress in a pregnant @entity0 , operationally defined by the factor unwanted pregnancy, may interfere with fetal development and result in a higher incidence of @entity2 . The interference may occur directly via psycho-endocrinal or autonomous mechanisms or indirectly by the way in which the @entity0 might act in this situation of stress, e.g. attempts to provoke abortion, neglect of proper food intake, excessive smoking, or the abuse of @entity1 of drugs.

title: Influence of maternal distress during pregnancy on fetal XXXX .

answer: @entity2


abstract: UNASSIGNED: Benign @entity8 is a common disease. Although large @entity7 with obstructive symptoms including @entity6 are a clear indication for surgery, acute @entity5 , particularly in benign cervical @entity7 cases, is rare. We herein report the case of 46-year-old female with acute @entity5 . The @entity0 had a large and elastic @entity7 which was more pronounced on the left side of her neck, and surgery was scheduled for within a few months. Three months after the initial presentation, while still waiting for surgery, the @entity0 was brought to the emergency room due to @entity4 and breathing difficulty and was immediately intubated. A computed tomography (CT) scan revealed that the @entity2 was markedly compressed by a nodular lesion in the left lobe, and @entity1 was also evident. Total thyroidectomy was immediately performed via the supraclavicular approach. The @entity0 had an uneventful postoperative course and recovered well. The resected specimen included a well-encapsulated solid and cystic mass. Histopathological examination mainly revealed @entity7 . The present case suggests that benign asymptomatic @entity8 mostly located in the neck may cause acute @entity5 , even if the nodules are not large. Early surgery should be performed when @entity9 and @entity3 due to a large @entity7 is prominent by CT scan.

title: Acute XXXX due to benign asymptomatic @entity8 in the cervical region: A case report.

answer: @entity5


abstract: UNASSIGNED: Benign @entity8 is a common disease. Although large @entity7 with obstructive symptoms including @entity6 are a clear indication for surgery, acute @entity5 , particularly in benign cervical @entity7 cases, is rare. We herein report the case of 46-year-old female with acute @entity5 . The @entity0 had a large and elastic @entity7 which was more pronounced on the left side of her neck, and surgery was scheduled for within a few months. Three months after the initial presentation, while still waiting for surgery, the @entity0 was brought to the emergency room due to @entity4 and breathing difficulty and was immediately intubated. A computed tomography (CT) scan revealed that the @entity2 was markedly compressed by a nodular lesion in the left lobe, and @entity1 was also evident. Total thyroidectomy was immediately performed via the supraclavicular approach. The @entity0 had an uneventful postoperative course and recovered well. The resected specimen included a well-encapsulated solid and cystic mass. Histopathological examination mainly revealed @entity7 . The present case suggests that benign asymptomatic @entity8 mostly located in the neck may cause acute @entity5 , even if the nodules are not large. Early surgery should be performed when @entity9 and @entity3 due to a large @entity7 is prominent by CT scan.

title: Acute @entity5 due to benign asymptomatic XXXX in the cervical region: A case report.

answer: @entity8


abstract: Aging disrupts skin barrier function and induces xerosis accompanied by @entity4 . In many cases, elderly @entity0 complain of @entity4 during skin hygiene care, a condition called aquagenic @entity4 of the elderly (APE). To date, the pathophysiology and mechanism of action of APE have not been elucidated. We conducted the present study to test the hypothesis that hypo-osmotic shock of epidermal cells induces @entity1 and elongation of C-fibers by @entity5 ( @entity5 ) as a basic mechanism of APE. The dorsal skin of HWY @entity2 , which are a model for disrupted skin barrier function, was treated with distilled water ( @entity6 treatment [Hypo] group) or normal saline (isotonic treatment [Iso] group) by applying soaked gauze for 7 days. Untreated @entity2 were used as a control (no-treatment [NT] group). Histochemical and immunohistochemical analyses revealed inflammatory responses in the epidermis and the dermal papillary layer in the Hypo group, while no alterations were observed in the Iso or NT groups. Induction of expression and secretion of @entity5 and elongation of C-fibers into the epidermis were found in the Hypo group. In contrast, secretion of @entity5 was significantly lower and elongation of C-fibers was not observed in the Iso group. These results suggest that hypo-osmotic shock-induced inflammatory reactions promote @entity3 to @entity4 in skin with disrupted barrier function.

title: Hypo-osmotic Shock-Induced Subclinical Inflammation of Skin in a XXXX Model of Disrupted Skin Barrier Function.

answer: @entity2


abstract: BACKGROUND: Previous interventions targeting nosocomial @entity1 have reduced catheterization and infections, but they require significant resources and may be susceptible to misclassification and surveillance bias. We sought to determine the effectiveness of a novel intervention at reducing catheterization and infections while exploring the potential for bias. METHODS: We conducted a prospective study of a brief monthly in- @entity0 educational intervention focusing on appropriate urinary catheter use. RESULTS: We studied 1,335 @entity0 (13,753 @entity0 days) on 1 control and 1 intervention ward. After the intervention, the device utilization rate was significantly reduced, with a relative risk of 0.49 (95% confidence interval [CI], 0.32-0.76; P  =  .001) versus 1.02 (95% CI, 0.58-1.82; P  =  .93) for controls. Both wards demonstrated a reduction in @entity3 after intervention, with an intervention relative risk of 0.42 (95% CI, 0.16-1.08; P  =  .07) and 0.51 (95% CI, 0.22-1.20; P  =  .12) for controls. There was no change in the rate of all nosocomial urine infections, with an intervention relative risk of 0.79 (95% CI, 0.38-1.65; P  =  .53) and 0.89 (95% CI, 0.48-1.67; P  =  .72) for controls. CONCLUSION: Our study demonstrates that our novel educational intervention significantly reduces urinary catheter use in hospitalized @entity0 . The trend towards reduced @entity3 after intervention, coupled with the absence of an improvement in all @entity2 supports a potential role of misclassification bias. We suggest that future prospective investigations explore this phenomenon using more robust outcome measures.

title: Novel low-resource intervention reduces urinary catheter use and associated XXXX : Role of outcome measure bias?

answer: @entity1


abstract: AIMS: To determine maternal and perinatal outcome of @entity6 @entity0 over a decade. METHODS: Analysis of case records of all @entity6 cases from January 2005 to December 2014. RESULTS: There were 30 cases of @entity6 . The most significant risk factors for developing @entity4 are unbooked cases (97%), nulliparity, young age, marriage    <=4 months, history of @entity4 in previous pregnancy, remarriage, preexisting @entity1 , interval between pregnancies   >= 10 years, positive family history. The incidence of @entity6 was 0.05%, @entity8 (50%), intrapartum 6 (20%) and postpartum 9 (30%) with no maternal deaths, and 1 perinatal @entity2 . Perinatal mortality was 33.3/1000. 22 (73%) @entity0 received @entity5 ( @entity5 ) and 8 @entity0 (27%) received @entity7 , of which 1 had recurrence of @entity3 . All 15 antepartum cases were delivered by cesarean section as were 2 intrapartum. 13 (43%) of @entity0 delivered vaginally. Only 6 (20%) @entity0 were of low socio-economic status and were primary school educated. Severe maternal complications occurred in 8 (27%), with abruptio placentae being the most common 3 (38%). CONCLUSIONS: Incidence of @entity6 was low, with no maternal deaths. @entity5 was found to be highly effective. Lack of antenatal care is a major risk factor.

title: Maternal and perinatal outcome of XXXX over a decade at a tertiary hospital in Kuwait.

answer: @entity6


abstract: UNASSIGNED: Chemo-resistance is a clinical barrier to more effective anti- @entity3 therapy. In this context, @entity3 stem-like cells (CSCs) are thought to be chemo-resistant, resulting in @entity3 recurrence and distant @entity2 . Our hypothesis is that chemo-resistance in CSCs is driven, in part, by enhanced mitochondrial function. Here, we used breast cell lines and metastatic @entity0 @entity1 samples to begin to dissect the role of mitochondrial metabolism in conferring the CSC phenotype. More specifically, we employed fluorescent staining with MitoTracker (MT) to metabolically fractionate these cell lines into mito-high and mito-low sub-populations, by flow-cytometry. Interestingly, cells with high mitochondrial mass (mito-high) were specifically enriched in a number of known CSC markers, such as @entity6 dehydrogenase (ALDH) activity, and they were ESA+/ @entity7 -/low and formed mammospheres with higher efficiency. Large cell size is another independent characteristic of the stem cell phenotype; here, we observed a >2-fold increase in mitochondrial mass in large cells (>12- m), relative to the smaller cell population (4-8- m). Moreover, the mito-high cell population showed a 2.4-fold enrichment in @entity3 -initiating cell activity, based on limiting dilution assays in @entity4 xenografts. Importantly, primary @entity1 breast CSCs isolated from @entity1 with metastatic @entity0 or a @entity1 derived xenograft (PDX) also showed the co-enrichment of ALDH activity and mitochondrial mass. Most significantly, our investigations demonstrated that mito-high cells were resistant to @entity5 , resulting in little or no DNA damage, as measured using the comet assay. In summary, increased mitochondrial mass in a sub-population of @entity0 cells confers a stem-like phenotype and chemo-resistance. As such, our current findings have important clinical implications for over-coming drug resistance, by therapeutically targeting the mito-high CSC population.

title: High mitochondrial mass identifies a sub-population of stem-like XXXX cells that are chemo-resistant.

answer: @entity3


abstract: UNASSIGNED: The neuronal receptor protein @entity4 phosphatase receptor    ( @entity5  ) inhibits axonal extension upon binding to chondroitin @entity3 proteoglycans (CSPGs) in scar tissue. We recently demonstrated that modulating or deleting @entity5   promoted re-innervation of the CSPG-containing @entity2 after @entity1 -reperfusion (I-R). However, it remains unknown if the lack of @entity5   or early treatment with the @entity5   modulator, intracellular sigma peptide (ISP), prevents the initial injury-induced axonal dieback. To address this, we carried out I-R in @entity5   -/- @entity0 or control littermates treated with ISP or vehicle immediately at the time of I-R, and then assessed sympathetic innervation of the scar and surrounding myocardium 3days later. Vehicle-treated WT controls displayed sympathetic denervation within the scar and viable tissue adjacent to the scar, as well as distal myocardium farther from the scar. @entity5   -/- and ISP-treated animals also displayed denervation of the scar and adjacent tissue, but regions distal to the scar were innervated normally. This suggests that @entity5   does not mediate axonal dieback but its disruption enhances axonal regrowth in the heart. CSPG digestion alters the macrophage response to prevent axonal dieback in spinal neurons, so we investigated whether targeting @entity5   might alter the macrophage response in the heart. The macrophage response after I-R was similar in vehicle and ISP-treated groups. @entity0 lacking @entity5   trended toward an increased M2 response, but were not significantly different than the other groups. These data suggest that @entity5   is not involved in axonal dieback or the early macrophage response following cardiac I-R.

title: Disrupting protein XXXX phosphatase    does not prevent sympathetic axonal dieback following myocardial infarction.

answer: @entity4


abstract: Findings from studies of @entity6 use with risk of @entity3 incidence and outcome provide mixed results; with few studies examined associations by recency of @entity4 diagnosis or duration of medication use. Thus, in the @entity1 's Health Initiative, we examined these associations and further explored whether associations differ by recency of @entity4 and duration of @entity6 use. Cox regression models were used to estimate hazard ratios (HR) and their 95% confidence intervals. @entity4 was associated with higher risk of @entity2 (HR, 1.13; p   <   0.001) and of several site-specific @entity3 (HR, 1.2-1.4, and up to over twofold). @entity4 was also associated with higher risk of @entity5 from @entity3 (HR, 1.46; p   <   0.001). There was no overall difference in @entity3 incidence by @entity4 therapy (p   =   0.66). However, there was a lower risk of @entity5 from @entity3 for @entity6 users, compared to users of other medications, relative to @entity1 without @entity4 , overall (HRs, 1.08 vs. 1.45; p   =   0.007) and for @entity0 (HRs, 0.50 vs. 1.29; p   =   0.05). Results also suggested that lower @entity3 risk associated with @entity6 may be evident only for a longer duration of use in certain @entity3 sites or subgroup populations. We provide further evidence that postmenopausal @entity1 with @entity4 are at higher risk of @entity2 and @entity3 @entity5 . @entity6 users, particularly long-term users, may be at lower risk of developing certain @entity3 and dying from @entity3 , compared to users of other anti- @entity4 medications. Future studies are needed to determine the long-term effect of @entity6 in @entity3 risk and survival from @entity3 .

title: @entity4 , @entity6 and incidence of and @entity5 from XXXX in postmenopausal @entity1 : Results from the @entity1 's health initiative.

answer: @entity2


abstract: Findings from studies of @entity6 use with risk of @entity3 incidence and outcome provide mixed results; with few studies examined associations by recency of @entity4 diagnosis or duration of medication use. Thus, in the @entity1 's Health Initiative, we examined these associations and further explored whether associations differ by recency of @entity4 and duration of @entity6 use. Cox regression models were used to estimate hazard ratios (HR) and their 95% confidence intervals. @entity4 was associated with higher risk of @entity2 (HR, 1.13; p   <   0.001) and of several site-specific @entity3 (HR, 1.2-1.4, and up to over twofold). @entity4 was also associated with higher risk of @entity5 from @entity3 (HR, 1.46; p   <   0.001). There was no overall difference in @entity3 incidence by @entity4 therapy (p   =   0.66). However, there was a lower risk of @entity5 from @entity3 for @entity6 users, compared to users of other medications, relative to @entity1 without @entity4 , overall (HRs, 1.08 vs. 1.45; p   =   0.007) and for @entity0 (HRs, 0.50 vs. 1.29; p   =   0.05). Results also suggested that lower @entity3 risk associated with @entity6 may be evident only for a longer duration of use in certain @entity3 sites or subgroup populations. We provide further evidence that postmenopausal @entity1 with @entity4 are at higher risk of @entity2 and @entity3 @entity5 . @entity6 users, particularly long-term users, may be at lower risk of developing certain @entity3 and dying from @entity3 , compared to users of other anti- @entity4 medications. Future studies are needed to determine the long-term effect of @entity6 in @entity3 risk and survival from @entity3 .

title: XXXX , @entity6 and incidence of and @entity5 from @entity2 in postmenopausal @entity1 : Results from the @entity1 's health initiative.

answer: @entity4


abstract: Findings from studies of @entity6 use with risk of @entity3 incidence and outcome provide mixed results; with few studies examined associations by recency of @entity4 diagnosis or duration of medication use. Thus, in the @entity1 's Health Initiative, we examined these associations and further explored whether associations differ by recency of @entity4 and duration of @entity6 use. Cox regression models were used to estimate hazard ratios (HR) and their 95% confidence intervals. @entity4 was associated with higher risk of @entity2 (HR, 1.13; p   <   0.001) and of several site-specific @entity3 (HR, 1.2-1.4, and up to over twofold). @entity4 was also associated with higher risk of @entity5 from @entity3 (HR, 1.46; p   <   0.001). There was no overall difference in @entity3 incidence by @entity4 therapy (p   =   0.66). However, there was a lower risk of @entity5 from @entity3 for @entity6 users, compared to users of other medications, relative to @entity1 without @entity4 , overall (HRs, 1.08 vs. 1.45; p   =   0.007) and for @entity0 (HRs, 0.50 vs. 1.29; p   =   0.05). Results also suggested that lower @entity3 risk associated with @entity6 may be evident only for a longer duration of use in certain @entity3 sites or subgroup populations. We provide further evidence that postmenopausal @entity1 with @entity4 are at higher risk of @entity2 and @entity3 @entity5 . @entity6 users, particularly long-term users, may be at lower risk of developing certain @entity3 and dying from @entity3 , compared to users of other anti- @entity4 medications. Future studies are needed to determine the long-term effect of @entity6 in @entity3 risk and survival from @entity3 .

title: @entity4 , @entity6 and incidence of and XXXX from @entity2 in postmenopausal @entity1 : Results from the @entity1 's health initiative.

answer: @entity5


abstract: Findings from studies of @entity6 use with risk of @entity3 incidence and outcome provide mixed results; with few studies examined associations by recency of @entity4 diagnosis or duration of medication use. Thus, in the @entity1 's Health Initiative, we examined these associations and further explored whether associations differ by recency of @entity4 and duration of @entity6 use. Cox regression models were used to estimate hazard ratios (HR) and their 95% confidence intervals. @entity4 was associated with higher risk of @entity2 (HR, 1.13; p   <   0.001) and of several site-specific @entity3 (HR, 1.2-1.4, and up to over twofold). @entity4 was also associated with higher risk of @entity5 from @entity3 (HR, 1.46; p   <   0.001). There was no overall difference in @entity3 incidence by @entity4 therapy (p   =   0.66). However, there was a lower risk of @entity5 from @entity3 for @entity6 users, compared to users of other medications, relative to @entity1 without @entity4 , overall (HRs, 1.08 vs. 1.45; p   =   0.007) and for @entity0 (HRs, 0.50 vs. 1.29; p   =   0.05). Results also suggested that lower @entity3 risk associated with @entity6 may be evident only for a longer duration of use in certain @entity3 sites or subgroup populations. We provide further evidence that postmenopausal @entity1 with @entity4 are at higher risk of @entity2 and @entity3 @entity5 . @entity6 users, particularly long-term users, may be at lower risk of developing certain @entity3 and dying from @entity3 , compared to users of other anti- @entity4 medications. Future studies are needed to determine the long-term effect of @entity6 in @entity3 risk and survival from @entity3 .

title: @entity4 , XXXX and incidence of and @entity5 from @entity2 in postmenopausal @entity1 : Results from the @entity1 's health initiative.

answer: @entity6


abstract: Findings from studies of @entity6 use with risk of @entity3 incidence and outcome provide mixed results; with few studies examined associations by recency of @entity4 diagnosis or duration of medication use. Thus, in the @entity1 's Health Initiative, we examined these associations and further explored whether associations differ by recency of @entity4 and duration of @entity6 use. Cox regression models were used to estimate hazard ratios (HR) and their 95% confidence intervals. @entity4 was associated with higher risk of @entity2 (HR, 1.13; p   <   0.001) and of several site-specific @entity3 (HR, 1.2-1.4, and up to over twofold). @entity4 was also associated with higher risk of @entity5 from @entity3 (HR, 1.46; p   <   0.001). There was no overall difference in @entity3 incidence by @entity4 therapy (p   =   0.66). However, there was a lower risk of @entity5 from @entity3 for @entity6 users, compared to users of other medications, relative to @entity1 without @entity4 , overall (HRs, 1.08 vs. 1.45; p   =   0.007) and for @entity0 (HRs, 0.50 vs. 1.29; p   =   0.05). Results also suggested that lower @entity3 risk associated with @entity6 may be evident only for a longer duration of use in certain @entity3 sites or subgroup populations. We provide further evidence that postmenopausal @entity1 with @entity4 are at higher risk of @entity2 and @entity3 @entity5 . @entity6 users, particularly long-term users, may be at lower risk of developing certain @entity3 and dying from @entity3 , compared to users of other anti- @entity4 medications. Future studies are needed to determine the long-term effect of @entity6 in @entity3 risk and survival from @entity3 .

title: @entity4 , @entity6 and incidence of and @entity5 from @entity2 in postmenopausal XXXX : Results from the @entity1 's health initiative.

answer: @entity1


abstract: Findings from studies of @entity6 use with risk of @entity3 incidence and outcome provide mixed results; with few studies examined associations by recency of @entity4 diagnosis or duration of medication use. Thus, in the @entity1 's Health Initiative, we examined these associations and further explored whether associations differ by recency of @entity4 and duration of @entity6 use. Cox regression models were used to estimate hazard ratios (HR) and their 95% confidence intervals. @entity4 was associated with higher risk of @entity2 (HR, 1.13; p   <   0.001) and of several site-specific @entity3 (HR, 1.2-1.4, and up to over twofold). @entity4 was also associated with higher risk of @entity5 from @entity3 (HR, 1.46; p   <   0.001). There was no overall difference in @entity3 incidence by @entity4 therapy (p   =   0.66). However, there was a lower risk of @entity5 from @entity3 for @entity6 users, compared to users of other medications, relative to @entity1 without @entity4 , overall (HRs, 1.08 vs. 1.45; p   =   0.007) and for @entity0 (HRs, 0.50 vs. 1.29; p   =   0.05). Results also suggested that lower @entity3 risk associated with @entity6 may be evident only for a longer duration of use in certain @entity3 sites or subgroup populations. We provide further evidence that postmenopausal @entity1 with @entity4 are at higher risk of @entity2 and @entity3 @entity5 . @entity6 users, particularly long-term users, may be at lower risk of developing certain @entity3 and dying from @entity3 , compared to users of other anti- @entity4 medications. Future studies are needed to determine the long-term effect of @entity6 in @entity3 risk and survival from @entity3 .

title: @entity4 , @entity6 and incidence of and @entity5 from @entity2 in postmenopausal @entity1 : Results from the XXXX 's health initiative.

answer: @entity1


abstract: BACKGROUND AND PURPOSE: The pathogenesis of poststroke fatigue is unclear. In this prospective study, we explored whether reduced physical activity might contribute to poststroke fatigue or be a consequence of it. METHODS: @entity0 with a recent acute @entity1 were assessed at 1, 6, and 12 months with, @entity4 ( @entity4 ), a @entity4 , @entity2 and @entity3 Score, sleepiness, quality of life, and accelerometry (ActivPAL). Bivariate analyses determined associations between fatigue and step count at each time point. Multiple linear regression tested whether 1-month step count independently predicted 6- and 12-month @entity4 . RESULTS: A total of 136 @entity0 (mean age, 72 years; 64% @entity0 ) attended >= 1 assessment. ActivPAL data were available for 84 (64%), 69 (66%), and 58 (64%) @entity0 at 1, 6, and 12 months, respectively. At 6 and 12 months, a positive @entity4 was associated with lower daily step counts (P=0.014 and 0.013, respectively). At 1, 6, and 12 months, higher @entity4 (more fatigue) was associated with lower step count (P<0.001, 0.01, and 0.007), higher @entity3 (P<0.001), @entity2 (P<0.001), and poorer quality of life (P<0.001). Lower daily step count (P<0.002 and 0.006) and greater @entity2 (P<0.001 for both) at 1 month independently predicted higher @entity4 at 6 and 12 months. CONCLUSIONS: Lower step counts at 1 month independently predicted greater @entity4 for  <=12 months. Physical activity might be a therapeutic target for poststroke fatigue.

title: Exploratory longitudinal cohort study of associations of fatigue after XXXX .

answer: @entity1


abstract: UNASSIGNED: In 40% of cases of classical @entity2 (cHL), EBV-latency-II antigens (EBNA1/ @entity4 /LMP2A) are present (EBV(+) cHL) in the malignant cells and antigen presentation is intact. Previous studies have consistently shown that @entity3 *02 is protective in EBV(+) cHL, yet its role in disease pathogenesis is unknown. To explore the basis for this observation, gene expression was assessed in 33 cHL nodes. Interestingly, @entity1 and LMP2A expression were strongly correlated and, for a given LMP2A level, @entity1 was markedly elevated in @entity3 *02(-ve) versus @entity3 *02(+) EBV(+) cHL @entity0 , suggesting that LMP2A-specific @entity1 (+) T-cell anti-tumoral immunity may be relatively ineffective in @entity3 *02(-ve) EBV(+) cHL. To ascertain the impact of HLA-class I on EBV-latency antigen-specific immuno-dominance, we used a step-wise functional T-cell approach. In newly diagnosed EBV(+) cHL, the magnitude of ex vivo @entity4 /2A-specific @entity1 (+) T-cell responses was elevated in @entity3 *02(+) @entity0 . Furthermore, in a controlled in vitro assay, LMP2A-specific @entity1 (+) T-cells from healthy @entity3 *02 heterozygotes expanded to a greater extent with @entity3 *02-restricted compared to non- @entity3 *02-restricted cell lines. In an extensive analysis of HLA-class I-restricted immunity, immuno-dominant EBNA3A/3B/3C-specific @entity1 (+) T-cell responses were stimulated by numerous HLA-class I molecules, whereas the sub-dominant @entity4 /2A-specific responses were largely confined to @entity3 *02. Our results demonstrate that @entity3 *02 mediates a modest, but nonetheless stronger, EBV-specific @entity1 (+) T-cell response than non- @entity3 *02 alleles, an effect confined to EBV-latency-II antigens. Thus, the protective effect of @entity3 *02 against EBV(+) cHL is not a surrogate association, but reflects the impact of HLA-class I on EBV-latency-II antigen-specific @entity1 (+) T-cell hierarchies. This article is protected by copyright. All rights reserved.

title: The impact of HLA-class I and EBV-latency-II antigen-specific @entity1 (+) T-cells on the pathogenesis of EBV(+) XXXX .

answer: @entity2


abstract: UNASSIGNED: In 40% of cases of classical @entity2 (cHL), EBV-latency-II antigens (EBNA1/ @entity4 /LMP2A) are present (EBV(+) cHL) in the malignant cells and antigen presentation is intact. Previous studies have consistently shown that @entity3 *02 is protective in EBV(+) cHL, yet its role in disease pathogenesis is unknown. To explore the basis for this observation, gene expression was assessed in 33 cHL nodes. Interestingly, @entity1 and LMP2A expression were strongly correlated and, for a given LMP2A level, @entity1 was markedly elevated in @entity3 *02(-ve) versus @entity3 *02(+) EBV(+) cHL @entity0 , suggesting that LMP2A-specific @entity1 (+) T-cell anti-tumoral immunity may be relatively ineffective in @entity3 *02(-ve) EBV(+) cHL. To ascertain the impact of HLA-class I on EBV-latency antigen-specific immuno-dominance, we used a step-wise functional T-cell approach. In newly diagnosed EBV(+) cHL, the magnitude of ex vivo @entity4 /2A-specific @entity1 (+) T-cell responses was elevated in @entity3 *02(+) @entity0 . Furthermore, in a controlled in vitro assay, LMP2A-specific @entity1 (+) T-cells from healthy @entity3 *02 heterozygotes expanded to a greater extent with @entity3 *02-restricted compared to non- @entity3 *02-restricted cell lines. In an extensive analysis of HLA-class I-restricted immunity, immuno-dominant EBNA3A/3B/3C-specific @entity1 (+) T-cell responses were stimulated by numerous HLA-class I molecules, whereas the sub-dominant @entity4 /2A-specific responses were largely confined to @entity3 *02. Our results demonstrate that @entity3 *02 mediates a modest, but nonetheless stronger, EBV-specific @entity1 (+) T-cell response than non- @entity3 *02 alleles, an effect confined to EBV-latency-II antigens. Thus, the protective effect of @entity3 *02 against EBV(+) cHL is not a surrogate association, but reflects the impact of HLA-class I on EBV-latency-II antigen-specific @entity1 (+) T-cell hierarchies. This article is protected by copyright. All rights reserved.

title: The impact of HLA-class I and EBV-latency-II antigen-specific XXXX (+) T-cells on the pathogenesis of EBV(+) @entity2 .

answer: @entity1


abstract: OBJECTIVE: @entity2 ( @entity2 ) is a common comorbidity of @entity3 ( @entity3 ). Long-term consequences of @entity2 are not completely understood, and adhering to a gluten-free diet is a burden for many @entity0 . We investigated the effect of @entity2 on vascular risk factors in a large cohort of @entity3 @entity0 aged <20   yr. RESEARCH DESIGN AND METHODS: Within the @entity1 (DPV)- @entity1 registry, data were analyzed from 59   909   <   20-yr-old @entity3 @entity0 treated at 392 centers in Germany and Austria. A total of 974 @entity0 with @entity2 ( @entity2 ) were compared with 28   398 @entity0 without @entity2 with respect to blood pressure (BP), lipids, glycohemoglobin (HbA1c ), body mass index (BMI), and reported smoking behavior. RESULTS: @entity0 with @entity3 and @entity2 showed significantly lower high-density lipoprotein (HDL) cholesterol levels [median (interquartile range): 53.0 (43.0-62.6)   mg/dL] than @entity0 without @entity2 [55.0 (45.0-66.0)   mg/dL; p   <   0.01; p   <   0.001 after adjustment for confounding variables]. Systolic BP was lower in @entity0 with @entity2 [105.5 (100.0-112.5) mmHg] than in @entity0 without @entity2 [110.0 (102.0-117.0) mmHg; p   <   0.0001; p   <   0.001 after adjustment]. There were no significant differences regarding smoking behavior, BMI, or HbA1c . In a subgroup of 335 @entity0 with @entity2 , HDL cholesterol was measured 1 yr after diagnosis of @entity2 :HDL increased by 8% (p   <   0.01). CONCLUSION: Young @entity0 with @entity3 and @entity2 have lower HDL cholesterol values than @entity0 without @entity2 . As low HDL cholesterol is associated with vascular risk, our findings support screening for @entity2 and monitoring of HDL cholesterol in young @entity0 with @entity3 .

title: Vascular risk factors in @entity0 , adolescents, and young adults with XXXX complicated by celiac disease: results from the DPV initiative.

answer: @entity3


abstract: OBJECTIVE: @entity2 ( @entity2 ) is a common comorbidity of @entity3 ( @entity3 ). Long-term consequences of @entity2 are not completely understood, and adhering to a gluten-free diet is a burden for many @entity0 . We investigated the effect of @entity2 on vascular risk factors in a large cohort of @entity3 @entity0 aged <20   yr. RESEARCH DESIGN AND METHODS: Within the @entity1 (DPV)- @entity1 registry, data were analyzed from 59   909   <   20-yr-old @entity3 @entity0 treated at 392 centers in Germany and Austria. A total of 974 @entity0 with @entity2 ( @entity2 ) were compared with 28   398 @entity0 without @entity2 with respect to blood pressure (BP), lipids, glycohemoglobin (HbA1c ), body mass index (BMI), and reported smoking behavior. RESULTS: @entity0 with @entity3 and @entity2 showed significantly lower high-density lipoprotein (HDL) cholesterol levels [median (interquartile range): 53.0 (43.0-62.6)   mg/dL] than @entity0 without @entity2 [55.0 (45.0-66.0)   mg/dL; p   <   0.01; p   <   0.001 after adjustment for confounding variables]. Systolic BP was lower in @entity0 with @entity2 [105.5 (100.0-112.5) mmHg] than in @entity0 without @entity2 [110.0 (102.0-117.0) mmHg; p   <   0.0001; p   <   0.001 after adjustment]. There were no significant differences regarding smoking behavior, BMI, or HbA1c . In a subgroup of 335 @entity0 with @entity2 , HDL cholesterol was measured 1 yr after diagnosis of @entity2 :HDL increased by 8% (p   <   0.01). CONCLUSION: Young @entity0 with @entity3 and @entity2 have lower HDL cholesterol values than @entity0 without @entity2 . As low HDL cholesterol is associated with vascular risk, our findings support screening for @entity2 and monitoring of HDL cholesterol in young @entity0 with @entity3 .

title: Vascular risk factors in XXXX , adolescents, and young adults with @entity3 complicated by celiac disease: results from the DPV initiative.

answer: @entity0


abstract: BACKGROUND: @entity4 ( @entity4 ) are the preferred access for hemodialysis, however, there continues to be limited data guiding the surgical management of primary dialysis access creation in elderly @entity2 @entity0 . METHODS: This is an 8-year retrospective institutional study evaluating the operative and clinical characteristics of @entity0 70  years or above who underwent primary, first-ever, @entity4 or @entity5 ( @entity5 ) creation. RESULTS: There was no overall significant difference in @entity4 and @entity5 primary (P  =  0.127) and secondary (P  =  0.870) patency. @entity5 had higher graft loss secondary to infection (P  =  0.0002) and @entity3 (P  =  0.0213). Survival was less than 50% at 2  years for @entity4 and @entity5 @entity0 . An equal number of @entity4 and @entity5 @entity0 who died had functional access at the time of @entity1 (P  =  1.0000) with more @entity5 @entity0 using their graft (initiating dialysis) before @entity1 (P  =  0.0118). CONCLUSIONS: Elderly @entity0 patency rates for @entity4 and @entity5 are satisfactory and support surgical access creation; however, overall 2-year survival is low. An equal number of @entity4 and @entity5 @entity0 died with functioning surgical access, however, more @entity5 @entity0 initiated dialysis and successfully used their access. Accordingly, special consideration needs to be given with regard to estimated timing until dialysis and predicted @entity0 longevity. Delaying access creation until dialysis is needed and proceeding with @entity5 creation appears to be justified.

title: Hemodialysis Access in the Elderly: Outcomes among XXXX Older than Seventy.

answer: @entity0


abstract: BACKGROUND: Several approaches have been proposed for risk-stratification and primary prevention of @entity7 ( @entity7 ), but their comparative and cost-effectiveness is unknown. METHODS: We constructed a state-transition microsimulation model to compare multiple approaches to the primary prevention of @entity7 in a simulated cohort of @entity0 aged 45-75 and @entity0 55-75. Risk-stratification strategies included the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines on the treatment of blood @entity6 , the Adult Treatment Panel (ATP) III guidelines, and approaches based on coronary artery @entity8 (CAC) scoring and @entity11 ( @entity11 ). Additionally we assessed a treat-all strategy in which all individuals were prescribed either moderate-dose or high-dose statins and all males received low-dose @entity4 . Outcome measures included @entity7 events, costs, medication-related side effects, radiation-attributable @entity1 , and quality-adjusted-life-years (QALYs) over a 30-year timeframe. RESULTS: Treat-all with high-dose statins dominated all other strategies for both @entity0 and @entity0 , gaining 15.7 million QALYs, preventing 7.3 million @entity10 , and saving over  238 billion, compared to the status quo, far outweighing its associated adverse events including @entity9 , @entity3 , @entity5 , and new-onset @entity2 . ACC/AHA guidelines were more cost-effective than ATP III guidelines for both @entity0 and @entity0 despite placing 8.7 million more @entity0 on statins. For @entity0 at low @entity7 risk, treat-all with high-dose @entity12 was more likely to cause a statin-related adverse event than to prevent a @entity7 event. CONCLUSIONS: Despite leading to a greater proportion of the population placed on statin therapy, the ACC/AHA guidelines are more cost-effective than ATP III. Even so, at generic prices, treating all @entity0 and @entity0 with statins and all @entity0 with low-dose @entity4 appears to be more cost-effective than all risk-stratification approaches for the primary prevention of @entity7 . Especially for low- @entity7 risk @entity0 , decisions on the appropriate primary prevention strategy should be based on shared decision making between @entity0 and healthcare providers.

title: Strategies for Primary Prevention of @entity7 Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary XXXX Scoring, and @entity11 , and a Global Treat-All Strategy: A Comparative--Effectiveness Modeling Study.

answer: @entity8


abstract: BACKGROUND: Several approaches have been proposed for risk-stratification and primary prevention of @entity7 ( @entity7 ), but their comparative and cost-effectiveness is unknown. METHODS: We constructed a state-transition microsimulation model to compare multiple approaches to the primary prevention of @entity7 in a simulated cohort of @entity0 aged 45-75 and @entity0 55-75. Risk-stratification strategies included the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines on the treatment of blood @entity6 , the Adult Treatment Panel (ATP) III guidelines, and approaches based on coronary artery @entity8 (CAC) scoring and @entity11 ( @entity11 ). Additionally we assessed a treat-all strategy in which all individuals were prescribed either moderate-dose or high-dose statins and all males received low-dose @entity4 . Outcome measures included @entity7 events, costs, medication-related side effects, radiation-attributable @entity1 , and quality-adjusted-life-years (QALYs) over a 30-year timeframe. RESULTS: Treat-all with high-dose statins dominated all other strategies for both @entity0 and @entity0 , gaining 15.7 million QALYs, preventing 7.3 million @entity10 , and saving over  238 billion, compared to the status quo, far outweighing its associated adverse events including @entity9 , @entity3 , @entity5 , and new-onset @entity2 . ACC/AHA guidelines were more cost-effective than ATP III guidelines for both @entity0 and @entity0 despite placing 8.7 million more @entity0 on statins. For @entity0 at low @entity7 risk, treat-all with high-dose @entity12 was more likely to cause a statin-related adverse event than to prevent a @entity7 event. CONCLUSIONS: Despite leading to a greater proportion of the population placed on statin therapy, the ACC/AHA guidelines are more cost-effective than ATP III. Even so, at generic prices, treating all @entity0 and @entity0 with statins and all @entity0 with low-dose @entity4 appears to be more cost-effective than all risk-stratification approaches for the primary prevention of @entity7 . Especially for low- @entity7 risk @entity0 , decisions on the appropriate primary prevention strategy should be based on shared decision making between @entity0 and healthcare providers.

title: Strategies for Primary Prevention of XXXX Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary @entity8 Scoring, and @entity11 , and a Global Treat-All Strategy: A Comparative--Effectiveness Modeling Study.

answer: @entity7


abstract: BACKGROUND: Several approaches have been proposed for risk-stratification and primary prevention of @entity7 ( @entity7 ), but their comparative and cost-effectiveness is unknown. METHODS: We constructed a state-transition microsimulation model to compare multiple approaches to the primary prevention of @entity7 in a simulated cohort of @entity0 aged 45-75 and @entity0 55-75. Risk-stratification strategies included the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines on the treatment of blood @entity6 , the Adult Treatment Panel (ATP) III guidelines, and approaches based on coronary artery @entity8 (CAC) scoring and @entity11 ( @entity11 ). Additionally we assessed a treat-all strategy in which all individuals were prescribed either moderate-dose or high-dose statins and all males received low-dose @entity4 . Outcome measures included @entity7 events, costs, medication-related side effects, radiation-attributable @entity1 , and quality-adjusted-life-years (QALYs) over a 30-year timeframe. RESULTS: Treat-all with high-dose statins dominated all other strategies for both @entity0 and @entity0 , gaining 15.7 million QALYs, preventing 7.3 million @entity10 , and saving over  238 billion, compared to the status quo, far outweighing its associated adverse events including @entity9 , @entity3 , @entity5 , and new-onset @entity2 . ACC/AHA guidelines were more cost-effective than ATP III guidelines for both @entity0 and @entity0 despite placing 8.7 million more @entity0 on statins. For @entity0 at low @entity7 risk, treat-all with high-dose @entity12 was more likely to cause a statin-related adverse event than to prevent a @entity7 event. CONCLUSIONS: Despite leading to a greater proportion of the population placed on statin therapy, the ACC/AHA guidelines are more cost-effective than ATP III. Even so, at generic prices, treating all @entity0 and @entity0 with statins and all @entity0 with low-dose @entity4 appears to be more cost-effective than all risk-stratification approaches for the primary prevention of @entity7 . Especially for low- @entity7 risk @entity0 , decisions on the appropriate primary prevention strategy should be based on shared decision making between @entity0 and healthcare providers.

title: Strategies for Primary Prevention of @entity7 Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary @entity8 Scoring, and XXXX , and a Global Treat-All Strategy: A Comparative--Effectiveness Modeling Study.

answer: @entity11


abstract: OBJECTIVE: To perform a systematic review of studies comparing the Solomon versus selective techniques for fetoscopic laser ablation (FLA) to treat @entity2 ( @entity2 ) complicating monochorionic diamniotic twin pregnancies. METHODS: Electronic searches (inception-September 2014). Selected studies were of pregnancies undergoing FLA for @entity2 with reports on any of; recurrence of @entity2 , @entity1 ( @entity1 ) or survival. Three studies were included; two cohort studies and one @entity0 ( @entity0 ), which directly compared Solomon vs selective techniques for FLA. RESULTS: The odds ratios (OR) of recurrent @entity2 , Solomon vs selective technique in the two cohort studies (n   =   249) were 0.30 (95% CI 0.00, 4.46) and 0.45 (95% CI 0.07, 2.20). The 'Solomon' @entity0 (n   =   274) demonstrated a statistically significant reduction in recurrent @entity2 with the Solomon technique, OR 0.21 (95% CI 0.04, 0.98). The OR for the development of @entity1 following Solomon vs selective technique were 0.20 (95%CI 0.00, 2.46) and 0.61 (95%CI 0.05, 5.53) for the cohort studies and 0.16 (95% CI 0.05, 0.49) in the 'Solomon' @entity0 , again the results were only statistically significant in the @entity0 . The observational evidence suggested an overall better survival with Solomon technique, statistically significant for the survival of at least one twin. The @entity0 did not demonstrate a significant difference, probably due to small sample size and lack of power. CONCLUSION: This systematic review of observational, comparative cohort and @entity0 data suggests a trend towards a reduction in recurrent @entity2 and @entity1 and an increase in twin survival with no increase in complications or adverse events. This needs to be confirmed by an appropriately powered @entity0 with long-term neurological follow-up.

title: Comparison of Solomon technique against selective laser ablation for XXXX : a systematic review.

answer: @entity2


abstract: INTRODUCTION: The effectiveness of statin pretreatment in reducing the incidence of contrast induced @entity2 has been examined in some observational and randomized studies, yielding controversial results. AIM: This study sought to evaluate the role of @entity5 in prevention of contrast induced @entity2 in @entity1 @entity0 with mild to moderate @entity3 , undergoing elective percutaneous coronary intervention. METHODS: 130 @entity0 with mean glomerular filtration rate of 48.5    16 mL/minute/1.73m(2) were prospectively enrolled, then randomly (double blind) assigned in 1:1 ratio to receive @entity5 (80 mg daily for 48 hours) or placebo. Serum @entity4 _ glomerular filtration rate were measured pre-intervention, 72 hours and 10 days thereafter. An increase in serum @entity4 by >0.5 mg/dL (44.2  mol/l), or >25% of baseline value was considered as contrast induced @entity2 . RESULTS: Mean age of the study cohort was 56    5 years (males: 62%). Mean serum @entity4 level in the placebo group increased significantly 3 days after coronary intervention and declined on the 10(th) day to a level that did not differ significantly from the baseline level, but still higher. However, in @entity5 group, mean serum @entity4 level showed a non significant rise on the third day and then decreased to a level close to the baseline one, on the 10th day. Incidence of contrast induced @entity2 was 7.7% in @entity5 group _ 20% in the placebo group (P<0.05). CONCLUSION: @entity5 dose of 80 mg per day for 48 hours is associated with decreased incidence of contrast induced @entity2 in @entity1 @entity0 with @entity3 undergoing percutaneous coronary intervention. This article is protected by copyright. All rights reserved.

title: Impact of High Loading Dose of XXXX in @entity1 @entity0 with Renal Dysfunction Undergoing Elective Percutaneous Coronary Intervention: A Randomized Controlled Trial.

answer: @entity5


abstract: INTRODUCTION: The effectiveness of statin pretreatment in reducing the incidence of contrast induced @entity2 has been examined in some observational and randomized studies, yielding controversial results. AIM: This study sought to evaluate the role of @entity5 in prevention of contrast induced @entity2 in @entity1 @entity0 with mild to moderate @entity3 , undergoing elective percutaneous coronary intervention. METHODS: 130 @entity0 with mean glomerular filtration rate of 48.5    16 mL/minute/1.73m(2) were prospectively enrolled, then randomly (double blind) assigned in 1:1 ratio to receive @entity5 (80 mg daily for 48 hours) or placebo. Serum @entity4 _ glomerular filtration rate were measured pre-intervention, 72 hours and 10 days thereafter. An increase in serum @entity4 by >0.5 mg/dL (44.2  mol/l), or >25% of baseline value was considered as contrast induced @entity2 . RESULTS: Mean age of the study cohort was 56    5 years (males: 62%). Mean serum @entity4 level in the placebo group increased significantly 3 days after coronary intervention and declined on the 10(th) day to a level that did not differ significantly from the baseline level, but still higher. However, in @entity5 group, mean serum @entity4 level showed a non significant rise on the third day and then decreased to a level close to the baseline one, on the 10th day. Incidence of contrast induced @entity2 was 7.7% in @entity5 group _ 20% in the placebo group (P<0.05). CONCLUSION: @entity5 dose of 80 mg per day for 48 hours is associated with decreased incidence of contrast induced @entity2 in @entity1 @entity0 with @entity3 undergoing percutaneous coronary intervention. This article is protected by copyright. All rights reserved.

title: Impact of High Loading Dose of @entity5 in XXXX @entity0 with Renal Dysfunction Undergoing Elective Percutaneous Coronary Intervention: A Randomized Controlled Trial.

answer: @entity1


abstract: INTRODUCTION: The effectiveness of statin pretreatment in reducing the incidence of contrast induced @entity2 has been examined in some observational and randomized studies, yielding controversial results. AIM: This study sought to evaluate the role of @entity5 in prevention of contrast induced @entity2 in @entity1 @entity0 with mild to moderate @entity3 , undergoing elective percutaneous coronary intervention. METHODS: 130 @entity0 with mean glomerular filtration rate of 48.5    16 mL/minute/1.73m(2) were prospectively enrolled, then randomly (double blind) assigned in 1:1 ratio to receive @entity5 (80 mg daily for 48 hours) or placebo. Serum @entity4 _ glomerular filtration rate were measured pre-intervention, 72 hours and 10 days thereafter. An increase in serum @entity4 by >0.5 mg/dL (44.2  mol/l), or >25% of baseline value was considered as contrast induced @entity2 . RESULTS: Mean age of the study cohort was 56    5 years (males: 62%). Mean serum @entity4 level in the placebo group increased significantly 3 days after coronary intervention and declined on the 10(th) day to a level that did not differ significantly from the baseline level, but still higher. However, in @entity5 group, mean serum @entity4 level showed a non significant rise on the third day and then decreased to a level close to the baseline one, on the 10th day. Incidence of contrast induced @entity2 was 7.7% in @entity5 group _ 20% in the placebo group (P<0.05). CONCLUSION: @entity5 dose of 80 mg per day for 48 hours is associated with decreased incidence of contrast induced @entity2 in @entity1 @entity0 with @entity3 undergoing percutaneous coronary intervention. This article is protected by copyright. All rights reserved.

title: Impact of High Loading Dose of @entity5 in @entity1 XXXX with Renal Dysfunction Undergoing Elective Percutaneous Coronary Intervention: A Randomized Controlled Trial.

answer: @entity0


abstract: UNASSIGNED: Marginal zone @entity9 of the pulmonary mucosa-associated lymphoid tissue ( @entity4 ) is a common type of primary @entity5 , but is rare as a pulmonary @entity1 . In the present study, a 49-year-old male @entity0 was admitted to The First Affiliated Hospital of Xi'an JiaTong University (Xi'an, China) with a @entity4 in the right upper lung. The @entity0 was diagnosed with @entity4 subsequent to undergoing chest computed tomography (CT), a routine blood test, pathological and histological examinations, a transbronchial lung biopsy and bronchoscopy. A chest CT scan revealed right middle lobe consolidation and inflammatory signs, accompanied by @entity11 in the anterior basal segment of the upper lobe and CT angiogram signs. @entity6 and swollen mucosa were observed by bronchoscopy. The tissue section of the transbronchial lung biopsy specimens revealed diffusely infiltrated monocytoid B-cell lymphocytes and a @entity2 . The tissue was found to be positive for @entity10 ( @entity7 )20, @entity9 2 and @entity15 expression, but negative for CD3, @entity13 , @entity12 and k-light chain expression. @entity16 and @entity14 , located in the residual follicular dendritic cells, were detected by immunohistochemical staining. The clinical manifestations of @entity4 are non-specific and misdiagnosis frequently occurs in clinical practice. Therefore, an appropriate invasive biopsy procedure is necessary for early and accurate diagnosis of @entity4 . Clinical presentation that includes periodic @entity3 and distended bronchi in @entity4 may indicate a diagnosis of @entity8 . Pulmonary @entity8 belongs to the category of @entity5 and accurate clinical diagnosis is challenging. The results in the present study may provide additional evidence for the accurate diagnosis of this rare entity.

title: Marginal zone XXXX of the pulmonary mucosa-associated lymphoid tissue: A case report.

answer: @entity9


abstract: UNASSIGNED: The expression of T-box transcription factor 5 ( @entity4 ) has previously been observed in @entity0 @entity1 . The aim of the present study was to investigate @entity4 expression and its potential clinical significance in @entity2 ( @entity2 ). Using reverse transcription-quantitative polymerase chain reaction, the @entity4 mRNA expression levels in 30 pairs of surgically resected healthy gastric tissues and early stage (stages I and II) @entity2 tissues were evaluated. The @entity4 mRNA expression levels were increased in @entity2 stage I and II @entity1 tissues (P=0.01, n=30) compared with the matched adjacent non- @entity1 tissue. However, no significant difference was observed in @entity4 mRNA expression levels in matched adjacent non- @entity1 tissue compared with the @entity1 tissue from stage III and IV @entity2 samples (P=0.318, n=30). Immunohistochemical analysis for @entity4 expression was performed on 161 paraffin-embedded stage I and II @entity2 tissue blocks. Statistical analysis was performed to evaluate the associations between @entity4 expression, clinicopathological factors and prognosis. @entity0 with stage I and II @entity2 and @entity1 with high @entity4 expression levels presented poor @entity3 ( @entity3 ) rate (P=0.024). The Cox proportional hazards model analysis demonstrated that @entity4 expression was an independent risk factor (P=0.017). The present study indicates that high expression of @entity4 is associated with unfavorable @entity3 rates in @entity0 with stage I and II @entity2 . In conclusion, the expression of @entity4 may be a valuable biomarker for the selection of cases of high-risk stage I and II @entity2 .

title: High expression level of T-box transcription factor 5 predicts unfavorable survival in stage I and II XXXX .

answer: @entity2


abstract: @entity3 caused by @entity9 are poorly understood partially because a suitable animal model is not available for their study. In contrast, a @entity4 caused by defective osteoclasts ( @entity0 @entity8 ) is better understood, largely because of advances made with a @entity2 model of the disease. The avian form of @entity8 is caused by RNA @entity1 viruses, but the role of osteoblasts and osteoclasts is not clear. We have performed a morphometric analysis of osteopetrotic avian bone to provide basic information about changes in the cells of bones from animals developing the disease. @entity7 embryos were injected at 12 days of incubation with a @entity6 (MAV-2(0)) that induces @entity8 at a high frequency. Changes in bone volume were detected 14 days after @entity6 injection. By 3 weeks of age, the bone volumes of osteopetrotic chicks were 4.7-fold larger than controls. The mean caliper diameter of an osteoclast was the same in osteopetrotic and normal bone. The number of osteoclasts per tibia increased in osteopetrotic animals, but the density of osteoclasts decreased. The presence of an increased number of osteoclasts of a normal size rules out the possibility that the @entity6 causes @entity8 by selectively killing osteoclasts. The total bone-nonbone interface increased in @entity8 , and greater than 90 per cent of interface surface was devoted to bone deposition. These results indicate that avian @entity8 is an osteoblastic, proliferative @entity5 and may serve as an excellent animal model for @entity0 diseases in which osteoblasts increase in number.

title: A quantitative histologic study of avian osteopetrotic bone demonstrating normal osteoclast numbers and XXXX .

answer: @entity9


abstract: BACKGROUND AND OBJECTIVE: @entity0 is essential for biological systems at low concentrations and toxic at higher levels. Heavy metals and metalloids such as @entity0 are major contaminants in 40% of hazardous waste sites. Thus, bioremediation has been considered as an effective means of cleaning up of @entity0 -contaminated sites. MATERIALS AND METHODS: In this study, 30 strains were isolated from wastewater samples collected from @entity0 -contaminated sites in Qom, Iran using the enrichment culture technique. One bacterial strain designated QW4, identified as Proteus hauseri by morphological, biochemical and 16S rRNA gene sequencing was studied for its ability to tolerate different concentrations of @entity1 (100-800 mM). Also, the disk diffusion method was performed to determine resistance to some antibiotics. RESULTS: Strain QW4 showed maximum minimum inhibitory concentration (MIC) to @entity1 (760 mM). The maximum @entity1 removal was exhibited at 35   C, while the removal activity reduced by 30.7% and 37% at 25   C and 40   C, respectively. The optimum pH and shaking incubator for removal activity was shown to be 7.0 and 150 rpm, with 60.2% and 60.3%, respectively. This bacterial strain was resistant to some antibiotics. CONCLUSION: The concentration of toxic @entity1 (1000  g/ml) in the supernatant of the bacterial culture medium decreased by 100% after 2 days and the color of the medium changed to red due to the formation of less toxic elemental @entity0 . Also, our results imply that heavy metal pollution may contribute to increased antibiotic resistance through indirect selection.

title: High potential application in bioremediation of XXXX by Proteus hauseri strain QW4.

answer: @entity1


abstract: UNASSIGNED: The pathogenesis of @entity2 is extremely complex, and the expression and role of telomerase in @entity3 tissues remains unclear. The aim of the present study was to detect telomerase expression in nucleus pulposus tissues of @entity3 and to explore the correlation between telomerase expression and other factors typical of @entity2 . A total of 8 @entity0 with degenerative nucleus pulposus were included as the experimental group and compared with 8 control @entity0 without evident @entity2 . The expression of telomerase in nucleus pulposus tissues was detected by immunohistochemical staining. ELISA was performed to determine the differential expression of telomerase, type II collagen and chondroitin @entity1 between the two groups. In addition, a correlation analysis was performed to form associations between these factors. Finally, 5 cases in the experimental group and 5 in the control group were involved in the analysis. Immunohistochemistry results showed that telomerase expression in the experimental group was significantly lower compared to the control group and the percentage in the unit field of view showed significant differences between the two groups (P<0.05). Similarly, the ELISA test results showed lower expression levels of telomerase, type II collagen and @entity4 in the experimental group when compared with the control group (P<0.05). The correlation analysis revealed that telomerase was positively correlated with type II collagen and chondroitin @entity1 (correlation coefficients, 0.673 and 0.528, respectively; P<0.01). In conclusion, telomerase is involved in the degeneration process of nucleus pulposus tissue in lumbar discs and has a positive correlation with other factors typically associated with degeneration.

title: Expression and significance of telomerase in the nucleus pulposus tissues of XXXX .

answer: @entity3


abstract: OBJECTIVES: Our study sought to determine the time parents of febrile @entity0 under the age of five took to seek competent medical care. We also looked at the possible sociodemographic/ clinical factors that influenced this presentation. METHODS: Four hundred and nine under-fives presenting at the emergency unit with a history of @entity1 in the last 48 hours along with their mothers were recruited over four months. Relevant sociodemographic information as well as symptoms and duration of illness were obtained. Multinomial regression analysis was performed to determine the predictors of early and late presentation. RESULTS: Over half (57%) of @entity0 presented within 24 hours of onset of @entity1 . The mean age of the @entity0 and mothers were 22  15 months and 30  5 years, respectively. High social class ( @entity3 , 95% CI 1.6-26.4), @entity4 , 95% CI 5.7-65.6), @entity2 (OR 3.2, 95% CI 1.6-6.5) and appearance of other symptoms (OR 6.0, 95% CI 3.0-12.0) were significant predictors of early presentation. Secondary school education, belonging to another ethnic group, and non-resolution of @entity1 were significant predictors of late presentation. CONCLUSION: The majority of febrile under-fives came to the hospital to seek competent medical care within the first 24 hours of illness. However, there is a need for more parental education on early hospital presentation for parents of low socioeconomic status and educational background.

title: Sociodemographic and Clinical Determinants of Time to Care-Seeking Among Febrile XXXX Under-Five in North-Central Nigeria.

answer: @entity0


abstract: BACKGROUND: @entity5 has emerged as an important nosocomial pathogen. Hospital outbreaks of extensively drug resistant (XDR) A. baumannii are a great concern. OBJECTIVES: Aims of this study were to characterize the resistance determinants and genetic relatedness of (XDR) A. baumannii isolates in hospitals in Tehran, Iran. MATERIALS AND METHODS: During a three-year study, clinical isolates of A. baumannii were collected from two hospitals in Tehran, Iran. Susceptibility testing to antibiotics was performed by disk diffusion method and XDR A. baumannii isolates were identified. Genes' encoding for carbapenemase production and integrons were identified by PCR. MICs of @entity4 and @entity3 were determined by agar dilution. Multiple locus variable-number tandem repeat analysis (MLVA) typing was used to determine genetic relationships of XDR isolates. RESULTS: Using PCR for amplification of bla OXA-51 , 93.9% (123.131) of isolates were identified as A. baumannii and 24.4% (30.123) were XDR. These isolates were resistant to @entity1 , @entity2 , @entity8 , @entity0 , @entity12 , @entity7 , @entity10 and @entity9 . Thirty percent of the isolates were resistant to @entity13 . All isolates were susceptible to @entity6 and @entity11 , while 93.3% (28.30) possessed bla @entity14 -like and 6.7% (2.30) possessed bla OXA-24 -like. All isolates possessed insertion sequence (ISAba1) in the upstream region of the @entity14 -like gene. Almost 96.7% (29.30) of the isolates were positive for class I integron and 43.3% (13.30) for class II. These isolates were also positive for class I. Class III integron was not detected. MLVA typing of XDR isolates showed seven clonally complexes and 16 singletons. CONCLUSIONS: The population structure of the A. baumannii isolates in our hospitals was genetically diverse. A significant association between XDR pattern and presence of class 1 integron (P < 0.001) was found indicating that many antibiotic resistance determinants are involved in development of XDR strains.

title: Molecular Identification of Resistance Determinants, Integrons and Genetic Relatedness of Extensively Drug Resistant XXXX Isolated From Hospitals in Tehran, Iran.

answer: @entity5


abstract: UNASSIGNED: The aim of this study was to determine the role of curative resection in metastatic @entity2 ( @entity2 ) and determine the subset of @entity0 who may benefit from concurrent curative resection of primary and metastatic lesions. A total of 103 @entity0 diagnosed with synchronous liver and/or lung metastatic @entity2 at the Osaka Medical Center for @entity1 and @entity3 between 1983 and 2010 were retrospectively investigated. All the @entity0 underwent curative resection of the primary and metastatic lesions. The median follow-up time was 5.69 years. A total of 83 and 13 @entity0 had only liver or lung metastasis, respectively, whereas 7 @entity0 had synchronous liver and lung metastases. A total of 25 @entity0 (24.2%) had no recurrence following curative resection and 14 @entity0 (13.5%) received more than one re-resection for disease recurrence and survived without any further recurrence thereafter. The 5-year survival of liver or lung metastatic @entity2 was 43.7 or 90.0%, respectively. However, the median @entity4 ( @entity4 ) in @entity0 with synchronous liver and lung metastases was 20.7 months. In the univariate and multivariate analyses, @entity1 invasion, synchronous liver and lung metastases and time-to-recurrence after the first curative resection were significantly associated with @entity4 and disease-free survival. In conclusion, curative resection confers longer-term survival in @entity0 with liver or lung metastatic @entity2 .

title: Clinicopathological characteristics and prognosis of stage IV XXXX .

answer: @entity2


abstract: UNASSIGNED: In this study, we sought to determine the predictors of pathological complete response (pCR) and compare the chemotherapeutic regimens administered to @entity0 @entity1 with and those without pCR. We retrospectively reviewed the data of 879 @entity1 treated at the Alvin J. Siteman @entity2 Center between 2006 and 2010, to identify @entity1 who were diagnosed with primary @entity0 and received neoadjuvant chemotherapy. @entity1 who received only neoadjuvant endocrine therapy were considered to be ineligible. @entity1 , @entity2 , and treatment characteristics, including type of chemotherapy, were compared between @entity1 who did and those who did not achieve pCR using Chi-square or Fishers exact tests and multivariate logistic regression analysis. Two-sided P-values of <0.05 were considered significant. Of the 333 @entity1 who met the inclusion criteria, 61 (18.3%) had documented pCR. Compared with @entity1 not achieving pCR, a greater proportion of @entity1 with pCR had @entity3 (80.3 vs. 68%, P=0.057), had poorly differentiated (grade 3) @entity2 (82 vs. 59.2%, P<0.001), had negative lymph node involvement (41 vs. 34%, P=0.0004) and had @entity2 that were @entity4 -amplified (41 vs. 23.5%, P=0.0054). A greater proportion of @entity1 with pCR received @entity5 -based chemotherapy (23 vs. 12.5%, P=0.016) or trastuzumab in conjunction with chemotherapy (41.0 vs. 16.9%, P<0.001). No @entity1 receiving solely @entity6 -based therapy achieved pCR in our study. Our study demonstrated that, for @entity0 , lower stage, negative lymph node involvement and @entity4 receptor amplification were each associated with pCR. @entity5 therapy and the concurrent use of trastuzumab were also associated with a higher likelihood of pCR.

title: Predictors of pathological complete response to neoadjuvant chemotherapy in XXXX : The impact of chemotherapeutic regimen.

answer: @entity0


abstract: OBJECTIVES: We aimed to evaluate the safety and effectiveness of the novel abluminal groove-filled biodegradable polymer-coated @entity6 -eluting FIREHAWK stent (MicroPort Medical, Shanghai, China) in a large cohort of @entity0 . BACKGROUND: Trials on the FIREHAWK stent allowing targeted @entity6 release were not individually powered to reliably estimate low-frequency safety endpoints such as stent @entity5 (ST) or to examine long-term safety and efficacy. Additionally, the China Food and Drug Administration requires an objective performance criterion (OPC) study for new drug-eluting stents. METHODS: The primary endpoint, @entity2 ( @entity2 ), was defined as the composite of @entity3 , target vessel @entity4 ( @entity4 ), or clinically indicated @entity1 revascularization at 12 months. @entity0 -level data from 1,007 @entity0 with de novo native coronary lesions exclusively treated with the FIREHAWK stent in the TARGET serial studies (I and II) were prospectively collected, pooled and analyzed throughout a 2-year follow-up. RESULTS: The 12-month rate of @entity2 in 1,003 @entity0 (follow-up rate, 99.6%) was 3.9% (upper 95% confidence interval (CI): 5.3%), which was significantly lower than the performance goal of 9.0% (P   <   0.0001). The 24-month rates of @entity2 , PoCE (a composite of all-cause death, all @entity4 , or any revascularization), and @entity7 definite or probable ST were 4.6%, 7.8% and 0.1%, respectively. In subgroup analysis, long lesion (>= 30 mm) was an independent predictor of @entity2 within 2 years (hazard ratio [95%CI]: 2.44 [1.32, 4.53], P   <   0.01). CONCLUSIONS: This pooled, @entity0 -level analysis indicates that the FIREHAWK stent exhibits a promising 2-year efficacy and safety profile.    2015 Wiley Periodicals, Inc.

title: Safety and efficacy of a novel abluminal groove-filled biodegradable polymer XXXX -eluting stent for the treatment of de novo coronary lesions: Two-year results from a prospective @entity0 -level pooled analysis of TARGET trials.

answer: @entity6


abstract: OBJECTIVES: We aimed to evaluate the safety and effectiveness of the novel abluminal groove-filled biodegradable polymer-coated @entity6 -eluting FIREHAWK stent (MicroPort Medical, Shanghai, China) in a large cohort of @entity0 . BACKGROUND: Trials on the FIREHAWK stent allowing targeted @entity6 release were not individually powered to reliably estimate low-frequency safety endpoints such as stent @entity5 (ST) or to examine long-term safety and efficacy. Additionally, the China Food and Drug Administration requires an objective performance criterion (OPC) study for new drug-eluting stents. METHODS: The primary endpoint, @entity2 ( @entity2 ), was defined as the composite of @entity3 , target vessel @entity4 ( @entity4 ), or clinically indicated @entity1 revascularization at 12 months. @entity0 -level data from 1,007 @entity0 with de novo native coronary lesions exclusively treated with the FIREHAWK stent in the TARGET serial studies (I and II) were prospectively collected, pooled and analyzed throughout a 2-year follow-up. RESULTS: The 12-month rate of @entity2 in 1,003 @entity0 (follow-up rate, 99.6%) was 3.9% (upper 95% confidence interval (CI): 5.3%), which was significantly lower than the performance goal of 9.0% (P   <   0.0001). The 24-month rates of @entity2 , PoCE (a composite of all-cause death, all @entity4 , or any revascularization), and @entity7 definite or probable ST were 4.6%, 7.8% and 0.1%, respectively. In subgroup analysis, long lesion (>= 30 mm) was an independent predictor of @entity2 within 2 years (hazard ratio [95%CI]: 2.44 [1.32, 4.53], P   <   0.01). CONCLUSIONS: This pooled, @entity0 -level analysis indicates that the FIREHAWK stent exhibits a promising 2-year efficacy and safety profile.    2015 Wiley Periodicals, Inc.

title: Safety and efficacy of a novel abluminal groove-filled biodegradable polymer @entity6 -eluting stent for the treatment of de novo coronary lesions: Two-year results from a prospective XXXX -level pooled analysis of TARGET trials.

answer: @entity0


abstract: To identify radiographic and MR features of @entity1 ( @entity2 ) related to reduced hip extension during walking. Sixty six subjects, were stratified into those with (n   =   36, KL   =   2, 3) and without (n   =   30, KL   =   0, 1) radiographic @entity1 . Cartilage and labrum lesions were graded semi-quantitatively on hip MRI. Alpha angle and lateral center edge (LCE) angle were measured. Sagittal kinematics and kinetics were calculated during walking at speed of 1.35   m/s using 3-D motion capture. All subjects completed @entity3 and @entity2 Outcome Score (HOOS), timed up and go, and 6   min walk tests. Variables were compared between the two groups using one-way ANOVA (adjusting for age). Correlations of radiographic and MR parameters with peak hip extension were calculated. The @entity2 group was older, had greater @entity0 , and limitation of function. They also had lower peak hip extension and higher peak hip flexion; and worse acetabular and femoral cartilage lesions. Peak hip extension and flexion correlated with KL grade, cartilage lesions in the inferior and posterior femur. Reduced hip extension and greater hip flexion during walking are present in high functioning (HOOS   >   85%) individuals with mild-moderate @entity1 , and are associated with cartilage lesions.

title: Anatomic correlates of reduced hip extension during walking in individuals with mild-moderate XXXX .

answer: @entity1


abstract: BACKGROUND: Changes in mitral valve geometry in @entity0 with significant @entity1 ( @entity1 ) have not been evaluated. The aim of the present study was to assess the prevalence of significant secondary @entity2 ( @entity2 ; grade  >=   2) and the geometric characteristics of the mitral valve in @entity0 with moderate and severe @entity1 (grade >=  2) undergoing aortic valve and root surgery. METHODS: One-hundred twenty @entity0 (mean age, 54      15  years; 65% @entity0 ) with @entity1 grade >=  2 undergoing aortic valve and root surgery were retrospectively evaluated. The presence of @entity2 grade  >=   2 and geometry of the mitral valve were assessed on preoperative transthoracic echocardiography. Left ventricular (LV) dimensions and mitral valve geometry were compared between @entity0 with @entity2 grade  >=   2 and @entity0 without. RESULTS: @entity2 grade  >=   2 was present in 28 @entity0 (23%). @entity0 with @entity2 grade  >=   2 had higher European System for Cardiac Operative Risk Evaluation II scores and more often used b-blockers and diuretics than their counterparts. @entity0 with @entity2 grade  >=   2 had larger tenting areas (mean, 1.59      0.79 vs 1.25      0.41  cm(2); P  =  .003), larger inter-papillary muscle distances (mean, 28.4      9.5 vs 24.8      5.2  mm; P  =  .014), larger left atria (mean, 40.9      13.7 vs 32.0      12.2  mL/m(2); P  =  .002), and lower LV ejection fractions (mean, 47.3      12.2% vs 54.3    9.3%; P  =  .002) as compared to @entity0 with @entity2 grade  <  2. However, there were no differences in indexed LV volumes. On multivariate logistic regression analysis, LV ejection fraction (odds ratio, 0.94; 95% confidence interval, 0.89-0.99; P  =  .018) and indexed left atrial volume (odds ratio, 1.05; 95% confidence interval, 1.01-1.10; P  =  .019) remained independently associated with @entity2 grade  >=   2 after correcting for tenting area and inter-papillary muscle distance. CONCLUSIONS: Among @entity0 with @entity1 grade >=  2 undergoing aortic valve and root surgery, the prevalence of @entity2 grade  >=   2 was 23%. Lower LV ejection fraction and larger left atrial volume were independently associated with @entity2 grade  >=   2.

title: Mitral Valve Geometry Changes in @entity0 with XXXX .

answer: @entity1


abstract: BACKGROUND: Changes in mitral valve geometry in @entity0 with significant @entity1 ( @entity1 ) have not been evaluated. The aim of the present study was to assess the prevalence of significant secondary @entity2 ( @entity2 ; grade  >=   2) and the geometric characteristics of the mitral valve in @entity0 with moderate and severe @entity1 (grade >=  2) undergoing aortic valve and root surgery. METHODS: One-hundred twenty @entity0 (mean age, 54      15  years; 65% @entity0 ) with @entity1 grade >=  2 undergoing aortic valve and root surgery were retrospectively evaluated. The presence of @entity2 grade  >=   2 and geometry of the mitral valve were assessed on preoperative transthoracic echocardiography. Left ventricular (LV) dimensions and mitral valve geometry were compared between @entity0 with @entity2 grade  >=   2 and @entity0 without. RESULTS: @entity2 grade  >=   2 was present in 28 @entity0 (23%). @entity0 with @entity2 grade  >=   2 had higher European System for Cardiac Operative Risk Evaluation II scores and more often used b-blockers and diuretics than their counterparts. @entity0 with @entity2 grade  >=   2 had larger tenting areas (mean, 1.59      0.79 vs 1.25      0.41  cm(2); P  =  .003), larger inter-papillary muscle distances (mean, 28.4      9.5 vs 24.8      5.2  mm; P  =  .014), larger left atria (mean, 40.9      13.7 vs 32.0      12.2  mL/m(2); P  =  .002), and lower LV ejection fractions (mean, 47.3      12.2% vs 54.3    9.3%; P  =  .002) as compared to @entity0 with @entity2 grade  <  2. However, there were no differences in indexed LV volumes. On multivariate logistic regression analysis, LV ejection fraction (odds ratio, 0.94; 95% confidence interval, 0.89-0.99; P  =  .018) and indexed left atrial volume (odds ratio, 1.05; 95% confidence interval, 1.01-1.10; P  =  .019) remained independently associated with @entity2 grade  >=   2 after correcting for tenting area and inter-papillary muscle distance. CONCLUSIONS: Among @entity0 with @entity1 grade >=  2 undergoing aortic valve and root surgery, the prevalence of @entity2 grade  >=   2 was 23%. Lower LV ejection fraction and larger left atrial volume were independently associated with @entity2 grade  >=   2.

title: Mitral Valve Geometry Changes in XXXX with @entity1 .

answer: @entity0


abstract: UNASSIGNED: The application of antioxidants has been considered as an important and effective approach against conditions in which oxidative stress occurs. Especially, @entity5 (FA) is an important antioxidant which exerts potency against cellular damage in the presence of oxidants. In the current study, the resistance effect of FA on @entity2 ( @entity3 )-stressed @entity0 embryonic kidney 293 cells (HEK293) in vitro was investigated. FA (1  mM) increased HEK293 cells' viability and significantly reduced @entity3 -induced cellular apoptosis, which was confirmed with flow cytometry and morphological results. Cell cycle analysis indicated low percentage of sub-G0 population of FA-treated HEK293 cells that confirmed its resistance effect. The FA-treated HEK293 cells followed by @entity3 exposure resulted in decreased ROS levels compared to control ( @entity3 -treated only). The results indicated that pretreatment of FA on cell prior to @entity3 exposure could significantly improve cell survival and increase catalase (CAT) and @entity1 dismutase (SOD) levels. On the other hand, reduction in the levels of @entity4 and ROS was obvious. It can be concluded that FA may protect HEK293 cells from injury induced by @entity3 through regulation of intracellular antioxidant enzyme activities and cell cycle distribution. The reduction in mitochondrial membrane potential was also inhibited by FA treatment. These results suggested the importance of naturally occurring antioxidants such as FA in therapeutic intervention methodology against oxidative stress-related diseases.

title: @entity5 renders protection to HEK293 cells against oxidative damage and apoptosis induced by XXXX .

answer: @entity2


abstract: UNASSIGNED: The application of antioxidants has been considered as an important and effective approach against conditions in which oxidative stress occurs. Especially, @entity5 (FA) is an important antioxidant which exerts potency against cellular damage in the presence of oxidants. In the current study, the resistance effect of FA on @entity2 ( @entity3 )-stressed @entity0 embryonic kidney 293 cells (HEK293) in vitro was investigated. FA (1  mM) increased HEK293 cells' viability and significantly reduced @entity3 -induced cellular apoptosis, which was confirmed with flow cytometry and morphological results. Cell cycle analysis indicated low percentage of sub-G0 population of FA-treated HEK293 cells that confirmed its resistance effect. The FA-treated HEK293 cells followed by @entity3 exposure resulted in decreased ROS levels compared to control ( @entity3 -treated only). The results indicated that pretreatment of FA on cell prior to @entity3 exposure could significantly improve cell survival and increase catalase (CAT) and @entity1 dismutase (SOD) levels. On the other hand, reduction in the levels of @entity4 and ROS was obvious. It can be concluded that FA may protect HEK293 cells from injury induced by @entity3 through regulation of intracellular antioxidant enzyme activities and cell cycle distribution. The reduction in mitochondrial membrane potential was also inhibited by FA treatment. These results suggested the importance of naturally occurring antioxidants such as FA in therapeutic intervention methodology against oxidative stress-related diseases.

title: XXXX renders protection to HEK293 cells against oxidative damage and apoptosis induced by @entity2 .

answer: @entity5


abstract: AIM: @entity4 often recurs. Several studies have identified risk factors for recurrence, but to our knowledge, none have focused on risk factors in the clinical situation. The present study aimed to identify risk factors for the recurrence of @entity4 and to create a recurrence risk score. METHOD: Hospitalized @entity0 diagnosed with diverticular bleeding from 2008 to 2013 (N = 151) were included in a retrospective cohort study. Risk factors predicting re-bleeding were identified using multivariate analysis, and a risk score was developed using receiver operator characteristic (ROC) analysis. RESULTS: Recurrence was identified in 52 @entity0 (34.4%) at a median interval of 11.5 months. A history of @entity1 and @entity3 , a @entity2 on admission, and longer hospitalization period were significant risk factors for re-bleeding. We developed a re-bleeding risk score by using these 4 factors; the area under the curve of ROC curve was 0.8. With this risk score, if the cut-off point is 7, then the sensitivity is very high (94%; specificity: 26%); if the cutoff point is 14, the specificity is very high (97%; sensitivity: 40%). This enables the division of @entity0 into 3 groups: high risk, intermediate risk, and low risk. CONCLUSION: @entity4 often recurs, and @entity0 have high recurrence rates within short periods. Risk factors for re-bleeding include a history of @entity1 and @entity3 , @entity2 , and longer hospitalization period, and the risk score may supply useful information for clinicians to aid management.

title: Investigation of risk factors predicting recurrence of XXXX and development of a recurrence risk score.

answer: @entity4


abstract: UNASSIGNED: @entity4 , a photo-oxidation product in the atmosphere, and its monohydrate were characterized in the gas phase by pure rotational spectroscopy. High-resolution spectra were measured in the range of 5-14 Hz using a cavity-based molecular beam Fourier-transform microwave spectrometer. Possible conformers were identified computationally, at the @entity2 /6-311++G(2df,2pd) level of theory. For both species, one conformer was identified experimentally, and no @entity3 internal rotation splittings were observed, indicative of relatively high barriers to rotation. In the monomer, rocking of the @entity1 group is a large amplitude motion, characterized by a symmetrical double-well potential. This and other low-lying out-of-plane vibrations contribute to a significant ( @entity3 top-corrected) inertial defect (-1.09 amu   (2)). In the monohydrate, wagging of the free @entity0 atom of water is a second large amplitude motion, so the average structure is planar. As a result, no c-type transitions were observed. Water tunneling splittings were not observed, because the water rotation coordinate is characterized by an asymmetrical double-well potential. Since the minima are not degenerate, tunneling is precluded. Furthermore, a concerted tunneling path involving simultaneous rotation of the water moiety and rocking of the @entity1 group is precluded, because the hilltop along this coordinate is a virtual, rather than a real, saddle-point. Inter- and intramolecular non-covalent bonding is discussed in terms of the quantum theory of atoms in molecules. The percentage of @entity4 hydrated in the atmosphere is estimated to be about 0.1% using statistical thermodynamics.

title: Rotational spectroscopy of the atmospheric photo-oxidation product XXXX and its monohydrate.

answer: @entity4


abstract: OBJECTIVE: To investigate the association between receptor-interacting kinase protein 4 ( @entity6 ) relative copy number (RCN) and prognosis of stage III( @entity2 ( @entity2 ) @entity0 treated with @entity4 -based chemotherapy. METHODS: @entity6 RCN was determined by real-time PCR and then dichotomized into high @entity6 RCN group(n=35) and low @entity6 RCN group (n=104) using the third quartile as the cut-off point. @entity5 ( @entity5 ) and @entity5 ( @entity5 ) were compared between high and low @entity6 RCN groups. The subgroup prognostic analysis was also conducted based on @entity1 site. RESULTS: The median follow-up period was 49 months (ranged 4 to 98 months). @entity0 with high @entity6 RCN had poorer @entity5 than those with low @entity6 RCN, which reached marginal significance(median @entity5 , 43.0 months vs. 53.5 months, P=0.074). Meanwhile there was no significant difference of @entity5 between two groups (P=0.352). In @entity3 subgroup, high @entity6 RCN was significantly associated with poor @entity5 (median @entity5 , 31.5 months vs. 56.6 months, P=0.015) but not with @entity5 (P=0.135). In @entity1 subgroup, @entity6 RCN was not associated with both @entity5 and @entity5 (P=0.981, P=0.738). Multivariate analysis revealed that high @entity6 RCN was an independent prognostic factor of @entity5 in stage III( @entity2 @entity0 treated with @entity4 -based chemotherapy (HR=2.903, 95% CI: 1.275 to 6.610). CONCLUSION: @entity6 RCN is significantly associated with @entity5 in stage III( @entity3 @entity0 receiving @entity4 -based chemotherapy and may be a novel biomarker that can predict the efficacy of @entity4 in @entity3 @entity0 .

title: [Association between XXXX relative copy number and prognosis of @entity2 @entity0 after @entity4 -based chemotherapy].

answer: @entity6


abstract: OBJECTIVE: To investigate the association between receptor-interacting kinase protein 4 ( @entity6 ) relative copy number (RCN) and prognosis of stage III( @entity2 ( @entity2 ) @entity0 treated with @entity4 -based chemotherapy. METHODS: @entity6 RCN was determined by real-time PCR and then dichotomized into high @entity6 RCN group(n=35) and low @entity6 RCN group (n=104) using the third quartile as the cut-off point. @entity5 ( @entity5 ) and @entity5 ( @entity5 ) were compared between high and low @entity6 RCN groups. The subgroup prognostic analysis was also conducted based on @entity1 site. RESULTS: The median follow-up period was 49 months (ranged 4 to 98 months). @entity0 with high @entity6 RCN had poorer @entity5 than those with low @entity6 RCN, which reached marginal significance(median @entity5 , 43.0 months vs. 53.5 months, P=0.074). Meanwhile there was no significant difference of @entity5 between two groups (P=0.352). In @entity3 subgroup, high @entity6 RCN was significantly associated with poor @entity5 (median @entity5 , 31.5 months vs. 56.6 months, P=0.015) but not with @entity5 (P=0.135). In @entity1 subgroup, @entity6 RCN was not associated with both @entity5 and @entity5 (P=0.981, P=0.738). Multivariate analysis revealed that high @entity6 RCN was an independent prognostic factor of @entity5 in stage III( @entity2 @entity0 treated with @entity4 -based chemotherapy (HR=2.903, 95% CI: 1.275 to 6.610). CONCLUSION: @entity6 RCN is significantly associated with @entity5 in stage III( @entity3 @entity0 receiving @entity4 -based chemotherapy and may be a novel biomarker that can predict the efficacy of @entity4 in @entity3 @entity0 .

title: [Association between @entity6 relative copy number and prognosis of @entity2 @entity0 after XXXX -based chemotherapy].

answer: @entity4


abstract: OBJECTIVE: To investigate the association between receptor-interacting kinase protein 4 ( @entity6 ) relative copy number (RCN) and prognosis of stage III( @entity2 ( @entity2 ) @entity0 treated with @entity4 -based chemotherapy. METHODS: @entity6 RCN was determined by real-time PCR and then dichotomized into high @entity6 RCN group(n=35) and low @entity6 RCN group (n=104) using the third quartile as the cut-off point. @entity5 ( @entity5 ) and @entity5 ( @entity5 ) were compared between high and low @entity6 RCN groups. The subgroup prognostic analysis was also conducted based on @entity1 site. RESULTS: The median follow-up period was 49 months (ranged 4 to 98 months). @entity0 with high @entity6 RCN had poorer @entity5 than those with low @entity6 RCN, which reached marginal significance(median @entity5 , 43.0 months vs. 53.5 months, P=0.074). Meanwhile there was no significant difference of @entity5 between two groups (P=0.352). In @entity3 subgroup, high @entity6 RCN was significantly associated with poor @entity5 (median @entity5 , 31.5 months vs. 56.6 months, P=0.015) but not with @entity5 (P=0.135). In @entity1 subgroup, @entity6 RCN was not associated with both @entity5 and @entity5 (P=0.981, P=0.738). Multivariate analysis revealed that high @entity6 RCN was an independent prognostic factor of @entity5 in stage III( @entity2 @entity0 treated with @entity4 -based chemotherapy (HR=2.903, 95% CI: 1.275 to 6.610). CONCLUSION: @entity6 RCN is significantly associated with @entity5 in stage III( @entity3 @entity0 receiving @entity4 -based chemotherapy and may be a novel biomarker that can predict the efficacy of @entity4 in @entity3 @entity0 .

title: [Association between @entity6 relative copy number and prognosis of XXXX @entity0 after @entity4 -based chemotherapy].

answer: @entity2


abstract: OBJECTIVE: To investigate the association between receptor-interacting kinase protein 4 ( @entity6 ) relative copy number (RCN) and prognosis of stage III( @entity2 ( @entity2 ) @entity0 treated with @entity4 -based chemotherapy. METHODS: @entity6 RCN was determined by real-time PCR and then dichotomized into high @entity6 RCN group(n=35) and low @entity6 RCN group (n=104) using the third quartile as the cut-off point. @entity5 ( @entity5 ) and @entity5 ( @entity5 ) were compared between high and low @entity6 RCN groups. The subgroup prognostic analysis was also conducted based on @entity1 site. RESULTS: The median follow-up period was 49 months (ranged 4 to 98 months). @entity0 with high @entity6 RCN had poorer @entity5 than those with low @entity6 RCN, which reached marginal significance(median @entity5 , 43.0 months vs. 53.5 months, P=0.074). Meanwhile there was no significant difference of @entity5 between two groups (P=0.352). In @entity3 subgroup, high @entity6 RCN was significantly associated with poor @entity5 (median @entity5 , 31.5 months vs. 56.6 months, P=0.015) but not with @entity5 (P=0.135). In @entity1 subgroup, @entity6 RCN was not associated with both @entity5 and @entity5 (P=0.981, P=0.738). Multivariate analysis revealed that high @entity6 RCN was an independent prognostic factor of @entity5 in stage III( @entity2 @entity0 treated with @entity4 -based chemotherapy (HR=2.903, 95% CI: 1.275 to 6.610). CONCLUSION: @entity6 RCN is significantly associated with @entity5 in stage III( @entity3 @entity0 receiving @entity4 -based chemotherapy and may be a novel biomarker that can predict the efficacy of @entity4 in @entity3 @entity0 .

title: [Association between @entity6 relative copy number and prognosis of @entity2 XXXX after @entity4 -based chemotherapy].

answer: @entity0


abstract: OBJECTIVES: To evaluate oncological outcomes after combination intravesical therapy with @entity2 (GC) and @entity5 ( @entity6 ) in the setting of recurrent non-muscle-invasive @entity3 (NMIBC) after failure of previous intravesical therapy. @entity0 AND METHODS: We retrospectively identified @entity0 with recurrent NMIBC after previous intravesical therapy, who refused or were not candidates for cystectomy, between 2005 and 2011. GC and @entity6 were sequentially instilled weekly for 6-8  weeks. Data were collected regarding @entity0 demographics, @entity3 history, and number and type of intravesical therapies before GC/ @entity6 . Outcomes evaluated included time to recurrence and/or progression after GC/ @entity6 . Recurrence-free outcomes were estimated using the Kaplan-Meier method, and Cox proportional hazards regression models were used to test the association of clinicopathological features with outcomes. RESULTS: In all, 27 @entity0 were identified, 23 with high-risk disease (high-grade or @entity4 in  situ) and four with intermediate-risk disease (multifocal or recurrent low-grade). All @entity0 received prior intravesical therapy, and 17 @entity0 (63%) received multiple courses. Twenty-four @entity0 were treated with BCG. The median (range) disease-free survival of all @entity0 was 15.2 (1.7-39.3) months. Seventeen @entity0 (63%) developed recurrent @entity3 , a median of 15.2  months after therapy. One @entity0 progressed to muscle-invasive disease 5  months after treatment, and one developed @entity1 22  months after treatment. Three @entity0 went on to cystectomy. Ten @entity0 (37%) had no evidence of disease at last follow-up, with a median follow-up of 22.1  months. CONCLUSION: The combination of intravesical GC and @entity6 could offer durable recurrence-free survival to some @entity0 with recurrent NMIBC who are not candidates for, or refuse, cystectomy.

title: Intravesical @entity2 in combination with XXXX as salvage treatment in recurrent non-muscle-invasive @entity3 .

answer: @entity5


abstract: OBJECTIVES: To evaluate oncological outcomes after combination intravesical therapy with @entity2 (GC) and @entity5 ( @entity6 ) in the setting of recurrent non-muscle-invasive @entity3 (NMIBC) after failure of previous intravesical therapy. @entity0 AND METHODS: We retrospectively identified @entity0 with recurrent NMIBC after previous intravesical therapy, who refused or were not candidates for cystectomy, between 2005 and 2011. GC and @entity6 were sequentially instilled weekly for 6-8  weeks. Data were collected regarding @entity0 demographics, @entity3 history, and number and type of intravesical therapies before GC/ @entity6 . Outcomes evaluated included time to recurrence and/or progression after GC/ @entity6 . Recurrence-free outcomes were estimated using the Kaplan-Meier method, and Cox proportional hazards regression models were used to test the association of clinicopathological features with outcomes. RESULTS: In all, 27 @entity0 were identified, 23 with high-risk disease (high-grade or @entity4 in  situ) and four with intermediate-risk disease (multifocal or recurrent low-grade). All @entity0 received prior intravesical therapy, and 17 @entity0 (63%) received multiple courses. Twenty-four @entity0 were treated with BCG. The median (range) disease-free survival of all @entity0 was 15.2 (1.7-39.3) months. Seventeen @entity0 (63%) developed recurrent @entity3 , a median of 15.2  months after therapy. One @entity0 progressed to muscle-invasive disease 5  months after treatment, and one developed @entity1 22  months after treatment. Three @entity0 went on to cystectomy. Ten @entity0 (37%) had no evidence of disease at last follow-up, with a median follow-up of 22.1  months. CONCLUSION: The combination of intravesical GC and @entity6 could offer durable recurrence-free survival to some @entity0 with recurrent NMIBC who are not candidates for, or refuse, cystectomy.

title: Intravesical @entity2 in combination with @entity5 as salvage treatment in recurrent non-muscle-invasive XXXX .

answer: @entity3


abstract: OBJECTIVES: To evaluate oncological outcomes after combination intravesical therapy with @entity2 (GC) and @entity5 ( @entity6 ) in the setting of recurrent non-muscle-invasive @entity3 (NMIBC) after failure of previous intravesical therapy. @entity0 AND METHODS: We retrospectively identified @entity0 with recurrent NMIBC after previous intravesical therapy, who refused or were not candidates for cystectomy, between 2005 and 2011. GC and @entity6 were sequentially instilled weekly for 6-8  weeks. Data were collected regarding @entity0 demographics, @entity3 history, and number and type of intravesical therapies before GC/ @entity6 . Outcomes evaluated included time to recurrence and/or progression after GC/ @entity6 . Recurrence-free outcomes were estimated using the Kaplan-Meier method, and Cox proportional hazards regression models were used to test the association of clinicopathological features with outcomes. RESULTS: In all, 27 @entity0 were identified, 23 with high-risk disease (high-grade or @entity4 in  situ) and four with intermediate-risk disease (multifocal or recurrent low-grade). All @entity0 received prior intravesical therapy, and 17 @entity0 (63%) received multiple courses. Twenty-four @entity0 were treated with BCG. The median (range) disease-free survival of all @entity0 was 15.2 (1.7-39.3) months. Seventeen @entity0 (63%) developed recurrent @entity3 , a median of 15.2  months after therapy. One @entity0 progressed to muscle-invasive disease 5  months after treatment, and one developed @entity1 22  months after treatment. Three @entity0 went on to cystectomy. Ten @entity0 (37%) had no evidence of disease at last follow-up, with a median follow-up of 22.1  months. CONCLUSION: The combination of intravesical GC and @entity6 could offer durable recurrence-free survival to some @entity0 with recurrent NMIBC who are not candidates for, or refuse, cystectomy.

title: Intravesical XXXX in combination with @entity5 as salvage treatment in recurrent non-muscle-invasive @entity3 .

answer: @entity2